Preface to DMR special edition ‘Cannabinoid receptors and ligands:therapeutic drug development and abuse potential’

摘要

Evidence following decades of research into ligands acting at cannabinoid type-1 (CB1) and type-2 (CB2) receptors suggests that development of drugs in this class may exhibit potential therapeutic use for a diverse range of clinical indications including chronic pain (Lynch and Ware 2015), cancer (Guzman 2003), nausea (Parker et al. 2011), stroke (Fernandez-Ruiz et al. 2015), heart disease (Steffens et al. 2005), and epilepsy (Friedman and Devinsky 2015).